Active substanceGlycyrrhizic acid + PhospholipidsGlycyrrhizic acid + Phospholipids
Similar drugsTo uncover
  • Phosphogliv®
    lyophilizate in / in 
  • Phosphogliv®
    capsules inwards 
  • Phosphogliv® forte
    capsules inwards 
  • Essenciglive
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Dosage form: & nbspcapsules
    Composition:Per one capsule:

    active substances: phospholipids (lipoid C 80) (in terms of 100% substance) (the main component of phosphatidylcholine 73-79%) - 65 mg, sodium glycyrrhizinate (trisodium salt glycyrrhizic acid) - 35 mg;

    Excipients: cellulose microcrystalline - 141.2 mg, calcium carbonate - 204.7 mg, calcium stearate - 0.9 mg talc - 7.7 mg, silicon dioxide colloid (aerosil) - 5.5 mg, hard gelatin capsules - 96.0 mg [housing: dye sunset yellow (E110) - 1.0%, titanium dioxide (E171) - 1.0%, gelatin - up to 100.0%; lid: titanium dioxide (E171) - 0.2%, iron dye oxide black (E 172) - 3.5%, gelatin - up to 100.0%].

    Description:Capsules hard gelatinous №0, the capsule case is orange, the lid is black.
    The contents of the capsule are a granular powder from white with a slightly yellowish tinge to a light yellow color, with a weak specific odor.
    Pharmacotherapeutic group:hepatoprotective agent
    ATX: & nbsp

    A.05.B.A   Preparations for the treatment of liver diseases

    Pharmacodynamics:

    Phosphatidylcholine

    More than 90% of the ingested phospholipids are absorbed into the small intestine. Most of them are cleaved by phospholipase A to 1-acetyl-lysophosphatidylcholine, 50% of which undergoes reverse acetylation to polyunsaturated phosphatidylcholine during absorption in the intestinal mucosa. Polyunsaturated phosphatidylcholine with a current of lymph enters the blood, from where it mainly enters high-density lipoproteins into the liver.

    Pharmacokinetics in humans was studied with the help of dinolonelephosphatidylcholine with a radioactive label - 3H (choline part) and 14C (the rest of linoleic acid). Maximum concentration 3H is achieved in 6-24 hours, amounting to 19.9% ​​of the prescribed dose; 14C in 4-12 hours, amounting to 27.9%. The half-life of the choline component is 66 hours, the remainder of linoleic acid is 32 hours. In the stool, a 2% 3H and 4.5% 14FROM; in urine 6% 3H and the minimum amount 14C. Both isotopes are absorbed in the intestine by more than 90%.

    Glycyrrhizic acid

    After oral administration in the intestine under the influence of the enzyme P-glucuronidase, produced by bacteria of normal microflora,from glycyrrhizic acid, an active metabolite is formed-P-glycyrrheic acid, which is absorbed into the systemic circulation. In the blood, P-glycyrrhetic acid binds to albumin and is almost completely transported to the liver. Isolation of P-glycyrrhotic acid occurs predominantly with bile, in the residual quantity - with urine.

    According to experimental data, phospholipids improve the lipophilic properties of glycyrrhizic acid, increasing the intensity and speed of its absorption by more than 2 times.

    Pharmacokinetics:

    The components of the preparation are well absorbed in the intestine both in the form of whole molecules and bioactive hydrolysis products (unsaturated fatty acids, choline, glycyrrheic acid), which after absorption through the intestinal walls easily penetrate into the liver, lungs, skin and other organs.

    Indications:

    - Fatty degeneration of the liver (hepatosis), alcoholic, toxic, including medicinal, liver damage;

    - at composition of complex therapy of viral hepatitis, liver cirrhosis and psoriasis.

    Contraindications:

    - Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug;

    - antiphospholipid syndrome;

    - bVariability (data on efficiency and safety is not enough);

    - PThe period of breastfeeding (data on safety effectiveness is not enough);

    - dThe national age is under 12 years (data on efficiency and safety is not enough).

    Carefully:

    In patients with portal hypertension.

    In patients with arterial hypertension.

    If you have these diseases, you should consult your doctor before starting the drug.

    Dosing and Administration:

    Take inside, with food, without chewing, squeezed a small amount of liquid.

    The recommended dosing regimen in adults and children over 12 years is 2 capsules 3 times a day.

    Duration of use can be up to 6 months, on average - 3 months.

    Side effects:

    Usually the drug Phosphogliv ® transferred well, side effects develop very rarely, according to post-registration surveillance - a frequency of <1/10 000.

    Allergic reactions: skin rash, difficulty in nasal breathing, conjunctivitis, cough.

    From the cardiovascular system: transient (transient) increase in blood pressure, peripheral edema.

    From the side of the digestive system: dyspepsia (belching, nausea, bloating), abdominal discomfort.

    If these symptoms occur, stop taking the medication and consult a doctor.

    Overdose:

    No cases of overdose have been reported.

    Interaction:

    Not described.

    Special instructions:

    In case of high blood pressure should stop taking the drug and see a doctor.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not adversely affect the ability to drive vehicles and perform other work that requires an increased concentration of attention and speed of psychomotor reactions.

    Form release / dosage:

    Capsules.

    Packaging:

    For 30, 50, 100, 200 or 300 capsules in plastic containers with high-pressure polyethylene or propylene lids.

    10 capsules per contour cell packaging made of polyvinylchloride film and aluminum foil.

    1 container or 2, 3, 5 contour mesh packages together with instructions for use are placed in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 20 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    At the end of the expiration date the drug should not be used.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N002528 / 01
    Date of registration:12.07.2007
    The owner of the registration certificate:PHARMSTANDART-FORESTRY, OJSC PHARMSTANDART-FORESTRY, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp22.12.2015
    Illustrated instructions
      Instructions
      Up